

[\[Categorical Listing\]](#) [\[Numerical Listing\]](#)

This policy amends HA Policy [96-054](#)



THE ASSISTANT SECRETARY OF DEFENSE

WASHINGTON, DC 20301-1200

MAY 5, 1997

MEMORANDUM FOR SURGEON GENERAL OF THE ARMY
SURGEON GENERAL OF THE NAVY
SURGEON GENERAL OF THE AIR FORCE
COMMANDER, DEFENSE PERSONNEL SUPPORT CENTER

SUBJECT: Amendment to ASD(HA) [Policy 96-054](#), "Policy for Use of Hepatitis A Virus (HAV) Vaccine and Immune Globulin", dated August 12, 1996

The ASD(HA) policy for the use of Immune Globulin (IG) is amended to require written authorization from the ASD(HA) prior to the release of IG from Defense Personnel Support Center and Army-owned stocks. This measure is taken in light of deficiencies, reported to me by the Food and Drug Administration, relating to validation of manufacturing processes designed to assure product quality and sterility followed by the manufacturer in producing the two IG lots now stored in the depot.

The release of DoD-held IG will be considered only in the event of a domestic emergency, after consultation with the Department of Health and Human Services (in which case, the release of IG would be to that department), or military necessity, as determined by the Secretary of Defense. The Services will rely on commercial sources of IG for all other requirements.

Point of contact is CDR Jonathan Sherman at (703) 681-8910, DSN 761-8910 or jsherman@ha.osd.mil.

Edward D. Martin, M.D.

Acting Assistant Secretary of Defense

HA POLICY 97-047

[\[Top\]](#)

Last update: 1/11/1999